Diffuse leptomeningeal glioneuronal tumor has various clinical manifestations and is easily misdiagnosed. This article aims to describe the clinical features of a patient with diffuse leptomeningeal glioneuronal tumor misdiagnosed as optic neuromyelitis lineage disease (NMOSD), analyze the causes of misdiagnosis, and identify the disease with similar clinical manifestations. Adolescent women with decreased vision and headache, nausea, and vomiting were initially diagnosed as NMOSD. Immunotherapy was ineffective; enhanced MRI and cerebrospinal fluid cytology examination were completed and compared with classic meningeal carcinoma, NMOSD, multiple sclerosis, and Vogt-Koyanagi-Harada (VKH) syndrome. Diffuse leptomeningeal glioneuronal tumor was finally diagnosed in adolescent women with no history of tumor. Compared with NMOSD: no history of infection, no AQP4, MOG antibody, no spinal segmental abnormalities, immunotherapy was ineffective; compared with multiple sclerosis: no history of infection, no plaque, no oligoclonal antibody, immunotherapy was ineffective; compared with VKH syndrome: no history of infection, no fever, no treatment for immunotherapy; and compared with classic meningeal carcinoma: adolescents, no extracranial tumor lesions, super high protein, more different sugar excess. Patients with acute visual impairment should consider not only NMOSD, but also diffuse leptomeningeal glioneuronal tumor (DLGNT) and other diseases. DLGNT could not be excluded when CSF cytology and MRI plain scan were negative. The positive rate of malignant cells can only be increased by repeatedly sending fresh cerebrospinal fluid for examination; DLGNT needs to be differentiated from NMOSD, multiple sclerosis, VKH syndrome, and other diseases. Early diagnosis and molecular targeted therapy can improve the quality of life and prolong life.
Introduction
Meningeal carcinoma refers to a central nervous system tumor in which malignant tumor cells metastasize and diffusely infiltrate the pia mater and subarachnoid space, also known as cancerous meningitis. The primary lesions are often derived from lung cancer, breast cancer, melanoma, hematological malignancies, etc. [1, 2] . Diffuse leptomeningeal glioneuronal tumor (DLGNT) is a type of meningeal carcinoma. In recent years, with the prolongation of survival of cancer patients, its incidence is on the rise. The most common initial symptoms are headache, nausea, and vomiting; the lesions often involve the cerebral hemisphere, cranial nerve, spinal cord, and spinal nerve roots. In the optic nerve, damage is manifested as visual loss and eye movement disorder. Diagnosis relies mainly on cerebrospinal fluid cytology and brain-enhanced MRI. Due to the lack of specificity of clinical manifestations, the rate of clinical missed diagnosis and misdiagnosis was extremely high [3] .
Optic neuromyelitis lineage disease (NMOSD) is a demyelinating disease that mainly affects the optic nerve and spinal cord. Most patients progress stepwise, leading to blindness or paraplegia. Accounting for 1-22% of all demyelinating diseases, any age can be onset, the average age of onset being 30 to 40 years old and more common in women [4] . In terms of optic nerve damage, both eyes are often involved at the same time or in succession, and the visual acuity decreases with eyeball pain at the beginning. Acute cases involve partial or complete loss of vision in the eye within hours or days [5] . Current treatments for NMOSD include general immunosuppressive agents, plasma exchange, and B cell depletion. In the acute phase, hormone shock therapy is preferred. Plasma exchange can rapidly remove AQP4 antibodies and inflammatory factors in the circulatory system in about half of patients who fail to receive corticosteroid treatment. In addition, intravenous gamma globulin (IVIG) replacement therapy is also available. Drugs to prevent recurrence in the remission phase include oral glucocorticoid, azathioprine, mycophenolate, tacrolimus, cyclosporine, and other immunosuppressants [6, 7] . Most NMOSD can achieve a good prognosis after standard treatment. DLGNT should also be considered when MRI examination of the optic nerve and spinal cord is normal, and immunotherapy is ineffective.
This article describes adolescent female patients with decreased vision and headache as first symptoms. Her vision rapidly declined to the sense of no light, and the initial diagnosis was NMOSD. After hormone shock combined with IVIG treatment, the patient's condition did not relieve and progressed to numbness and weakness of both lower extremities, unable to walk, and urinary retention. An enhanced MRI showed that the meninges and spinal membranes were strengthened, so the possibility of meningeal carcinoma was considered; after repeated cerebrospinal fluid cytology examination, cancer cells were found, but the primary tumor was not found, according to the 2016 World Health Organization (WHO) classification of the central nervous system tumors [8] . Results conformed to the diffuse leptomeningeal glioneuronal tumor, the reasons of misdiagnosis were analyzed, and NMOSD, multiple sclerosis, Vogt-KoyanagiHarada syndrome (VKH syndrome), and other diseases with similar clinical manifestations were identified.
Object and Methods

Object
A 16-year-old adolescent female, 40 kg, was admitted to the hospital because of Bsight loss with headache for 20 days.T wenty days ago, the patient had no significant symptoms but blurred vision and headache appear, and this gradually increased, accompanied by nausea and vomiting. She had been treated in the Department of Gastroenterology at local clinics and county hospitals; the symptoms were gradually aggravating. She had progressive vision loss in both eyes and significant weakness in the lower extremities. For further diagnosis and treatment, she transferred to another hospital, the outpatient doctor initially diagnosed her with BNMOSD,^and she was admitted to the Department of Neurology. She had no previous health issues: no tumor history, no genetic history, no allergy history, etc.
Physical examination: T 36.8°C, lethargy, wheelchair pushed into the ward, no superficial lymph node enlargement, heart, lung and abdomen and limbs not seen with obvious positive signs. Neurological examination: poor memory, small palpebral fissure on the right side, bilateral pupils were not equal, right side diameter 5 mm, insensitive to light reflection, left side diameter 4 mm, slow light reflection, bilateral eye movements in all directions, no nystagmus, no manual before the eyes (1 m), bilateral frontal stria and nasolabial groove were symmetrical, tongue was in the middle, speaks clearly, pharyngeal reflex existed, double normal upper limb muscle strength and muscle tension were normal, double lower limbs strength level 3, low muscle tension, bilateral tendon reflex did not elicit, bilateral deep and shallow sensation and ataxia movement examination were normal, neck stiffness (5 transverse fingers), bilateral Kernig's sign, Brudzinski's sign positive, and the remaining pathological signs were negative.
The examination results after admission showed that the blood routine WBC were slightly higher than normal, and electrolytes, liver and kidney function, blood glucose, and thyroid function were normal. A brain CT showed mild hydrocephalus; chest and abdomen CT were normal; and electrocardiogram and electroencephalogram were normal. After dehydration treatment with mannitol, the patient's condition gradually worsened, with no light in her eyes and the lower limbs were difficult to lift off the bed surface. To trace the cause, cerebrospinal fluid and head and neck MRI examination was conducted.
Methods
Cerebrospinal Fluid Examination
Lumbar puncture was performed at L3-4 under local anesthesia, and cerebrospinal fluid was retained for examination: routine, biochemical, acid-proof staining, ink staining, sent cerebrospinal fluid 5 ml to Wuhan Kangshengda Company to check AQP4, MOG, autoimmune encephalitis, and paraneoplastic syndrome antibodies. We sent cerebrospinal fluid 5 ml to Huada Gene Company to check the pathogenic genes for viruses, bacteria, fungi, tuberculosis, and parasites by second-generation sequencing.
MRI Plain Scan and Enhancement of the Optic Nerve and Spinal Cord
The patient was placed in the supine position. Symphonyp3.0-T MRI of Siemens, Germany, was used to perform routine axial scanning of the craniocerebral region, and coronal or sagittal scanning was used according to the lesion location.
The scanning cross-section layer thickness was 6.0 mm, the pitch was 1 mm, and the sagittal layer thickness was 4.0 mm. The inspection sequence includes T1WI, T2WI, and FLAIR. When performing an enhanced scan, 0.1 mmol/kg of Gd-DTPA was injected by body weight, and then the axial, sagittal, and coronal images were collected, and the spinal cord was scanned in a sagittal position.
The patient was diagnosed with NMOSD. After IVIG and methylprednisolone shock treatment were given, the condition did not improve. In order to find out the cause, fresh cerebrospinal fluid was repeatedly sent for cytological examination.
Cytological Examination of Cerebrospinal Fluid
We collected 2 to 3 ml of cerebrospinal fluid and placed in a sterile tube, centrifuged at 100×g for 10 min at 4°C, decanted the supernatant, and left 500 μl of liquid at the bottom. After mixing the precipitate, it was aspirated approximately 200 μl of the mixed cerebrospinal fluid sample and transferred to an FMU-6 cell slide centrifuge. It was centrifuged at 1000 r/min for 5 min; the slides were taken out and after naturally drying, Wright's staining for 10 min, rinsed with running water for 10~15 s, dried, and then examined under a microscope. First, the whole film was scanned under a low-power microscope, and then the suspicious cells were transferred to an oil microscope for further identification.
Relevant Literature Search and Analysis
In databases such as PubMed, EMBASE, MEDLINE, ISI Web of Science, CNKI, VIP, and Wanfang, relevant original papers were retrieved, and the retrieval time was from the database construction to December 1, 2018. The search terms were as follows: BMeningeal carcinoma^, BOptic neuromyelitis lineage disease^, BMultiple sclerosis^, and BVogtKoyanagi-Harada syndrome.^The retrieval method was as follows: Subject words were combined with free words to collect relevant epidemiology, clinical manifestations, examination results, treatment, and prognosis of the above diseases in the literature. The clinical characteristics of the patient were compared with those of the above diseases.
Results
Cerebrospinal Fluid Examination Results
The cerebrospinal fluid pressure was much higher than 400 mmH 2 
Antibody Test Results
Autoimmune antibodies: nucleosome, double-stranded DNA, histone, SmD1, value-added nuclear antigen, ribosome, SSA/ Ro60kD, SSA/Ro52kD, SSB/La, CenpB, Scl70, Ul-snRNP, AMA-M2, Jo-1, PM-Scl, Mi-2, Ku antibodies were all negative. NMOSD-related antibodies: AQP4 and MOG were negative. Autoimmune encephalitis-related antibodies: NMDA-R-Ab, CASPR2-Ab, AMPA1-R-Ab, AMPA2-R-Ab, LGI1-Ab, GABA-R-Ab, and GAD65-Ab were all negative.
MRI Plain Scan and Enhanced Inspection Results
MRI plain scan of the brain: bilateral hippocampus, right thalamic abnormal signal, supratentorial ventricle slightly enlarged, bilateral inferior turbinate hypertrophy; Gd-DTPAenhanced scanning with injection: right thalamus lesion and meninges showed striated enhancement, with meninges enhancement in the basal cistern as the focus. MRI plain scan of the optic nerve: no abnormal lesions were seen on the bilateral ocular and optic nerve MRI scans. MRI plain scan of the cervical spine: normal sequence, physiological curvature, no obvious abnormalities in bone signal, no obvious signs of intervertebral disc herniation, no space occupying in the vertebral canal, no obvious abnormalities in cervical medulla morphology and signal, symmetrical diameter of the bilateral vertebral artery, normal flow void signal, no abnormalities in cervical soft tissue signal; GD-DTPA-enhanced scan of the cervical spine: thickened cervical medullary spinal membrane with striated enhancement. MRI plain scan of the thoracic spine: normal sequence, physiological curvature, no obvious abnormality in the intervertebral disc, no space occupying in the spinal canal, no obvious abnormality in the shape and signal of the thoracic spinal cord, no abnormality in the paravertebral soft tissue; thoracic GD-DTPA-enhanced scan: meningeal thickening with striated enhancement (see Fig. 1 for details).
The patient was diagnosed with NMOSD and given a hormonal shock (methylprednisolone 500 mg was used for 5 consecutive days, and then halved every 3 days) and IVIG (0.4 g/kg for 5 days), which improved the circulation. Trophic nerve eliminated oxygen free radicals, vitamin supplementation, stomach protection, and symptomatic supportive treatment, and the use of mannitol and glycerol fructose dehydration to reduce intracranial pressure was also done, but the patient's condition was progressively aggravated. Vision loss occurred. In order to save vision, intracranial pressure was reduced and to avoid hydrocephalus, an Ommaya sac was emergency placed for the continuous drainage of cerebrospinal fluid. Since the immunotherapy of the patient was ineffective, an enhanced MRI showed that the meninges and spinal membranes were strengthened, so the possibility of meningeal carcinoma was considered. For further diagnosis, fresh CSF was repeatedly sent for cytological examination.
Cytological Results of Cerebrospinal Fluid
Cerebrospinal fluid cytology (Wright's staining × 400, Fig. 2 ): tumor cells vary in size and deformity, some resemble naked nuclei, cells are not arranged neatly, appearing clusters; large nuclei, imbalance of nucleoplasm, nuclear morphology variable, lobulated, active nuclear division, abnormal mitosis; cytoplasm may be formed by pigment particles or special vacuoles; increased chromatin, coarse and basophilic particles; thickened nuclear membrane with jagged indentations and wear on the edges; the nucleolus is obvious and pleomorphic, accounting for the majority of chromatin.
Identification of Similar Diseases Such as NMOSD
Literature search was conducted to find the epidemiology, clinical manifestations, examination results, and treatment of meningeal carcinoma [3, 9] , NMOSD [4, 5, 10, 11] , multiple sclerosis [12, 13] , and Vogt-Koyanagi-Harada syndrome (VKH syndrome) [14] [15] [16] . The comparison with this patient is shown in Table 1 .
Discussion
The clinical manifestations of meningeal carcinoma are diverse and non-specific. Currently, the following diagnostic criteria are adopted: (1) definite tumor history; (2) new neurological symptoms and signs; (3) positive CSF cytology; (4) typical MRI manifestations. Anyone who has (1) or (2) and one of (3) or (4) can be diagnosed with meningeal carcinoma [9, 17] . Although CSF cytology found cancer cells are the gold standard for the diagnosis of this disease, the positive rate is low and it is often necessary to repeatedly send fresh cerebrospinal fluid to detect tumor cells, which makes it easy to delay diagnosis and treatment [18] . Cerebrospinal fluid cytology examination is often affected by many factors, such as the quantity, time, storage condition, concentration and Fig. 1 MRI plain scan and enhancement of cervical and thoracic medulla. 1-1, 1-3, MRI plain scan; 1-2, 1-4, MRIenhanced scan. Arrows, enhanced signal collection method, and tableting methods, resulting in a lower detection rate. Before the discovery of tumor cells, it was easy to confuse it with intracranial infectious diseases (tuberculosis, Cryptococcus neoformans) and immune system diseases (NMOSD, multiple sclerosis). However, cerebrospinal fluid cytology of DLGNT is usually negative, which poses new challenges for diagnosis. MRI has outstanding clinical value in the early diagnosis of meningeal carcinoma. The advantages are that there is no trauma and multi-directional multisequence imaging; however, the results lack specificity. When the patient does not have brain parenchymal metastasis, the cancer cells mainly infiltrate along the meninges, and the diffusely distributed lesion tissue and the adjacent brain tissue are absent as an obvious contrast, so MRI plain scan to find meningeal abnormalities is difficult and the patient can be easily misdiagnosed with tuberculous meningitis, cryptococcal meningitis, viral meningitis, etc. In summary, enhanced MRI is essential for the diagnosis of DLGNT, but the diagnosis requires a meningeal biopsy.
The course of untreated DLGNT is irreversible, and the median survival time is about 4-6 weeks. Cranial hypertension is an important factor affecting the prognosis and quality of life, as well as one of the important causes of death and disability in such patients. Early treatment of primary tumors is the main measure to prevent DLGNT. At present, the treatment of DLGNT is to relieve symptoms, improve quality of life, and prolong life. Treatment methods mainly include cerebrospinal fluid chemotherapy, radiotherapy, surgical treatment, systemic chemotherapy, and supportive treatment; however, most of the treatments can only alleviate clinical symptoms and have little effect on improving survival time [19] . Surgery has two main purposes: (1) patients are treated with intraventricular chemotherapy by burying Ommaya sac under the scalp; (2) ventriculo-peritoneal shunt is recommended for patients with stubborn high intracranial pressure. Compared with the traditional lumbar puncture, intraventricular chemotherapy through Ommaya sac has the advantages of simple operation, safety, and less pain and can make the chemotherapy drugs enter the cerebrospinal fluid at a balanced and uniform speed and maintain a stable blood concentration. Intrathecal chemotherapy, which allows drugs to bypass the blood-brain barrier and enter the subarachnoid space directly, is currently considered to be a reliable method for the treatment of DLGNT. In combination with other drugs on the basis of intrathecal injection, it may improve the quality of life and prolong survival. The main drugs include MTX, Ara-C, and tiotipide, among which temozolomide has a better effect. With the development of gene-targeted drugs, genetic testing of cerebrospinal fluid cancer cells and free DNA may provide more evidence for treatment. Current targeted therapies include the following: EGFR tyrosine kinase inhibitors, ALK inhibitors, HER2 monoclonal antibodies, and vascular endothelial growth factor monoclonal antibodies [20] [21] [22] .
NMOSD is a very serious autoimmune disease of the central nervous system, with high recurrence rate, high disability rate, and poor prognosis. As the disease progresses, more than half of patients with spinal cord injury will not be able to walk independently, and most patients with optic nerve damage will be blind. The discovery of a specific marker, AQP4-IgG, has played a landmark role in the study of NMOSD, which is attributed to the autoimmune ion channel disease [10, 11, 23, 24] . The pathogenesis of NMOSD is complex, and there is no effective cure at present. Once the diagnosis of NMOSD is considered, even mild symptoms should be treated as soon as possible. The binding of AQP4 antibodies to antigens is the central link of the disease occurrence. Restoring the body's immune homeostasis, inhibiting AQP4 antibody production, and blocking downstream-related immune responses have become important strategies for the treatment and prevention of the disease recurrence. Although traditional immunosuppressive agents are still irreplaceable therapeutic drugs at present, some patients cannot tolerate them due to their extensive immunosuppressive and bone marrow-suppressive effects. The NMOSD sequential therapy was performed with immunosuppressants such as mortemecophenolate, azathioprine, and rituximab [11] . When treating for NMOSD, patients should be alert to DLGNT if their symptoms do not improve significantly. Timely cerebrospinal fluid cytology and head-enhanced MRI examination, early diagnosis, and timely treatment can improve the quality of life and prolong life. This patient was an adolescent female with no history of cancer and no family history. Acute onset manifested as headache, nausea, and vomiting and decreased vision, accompanied by blurred consciousness and positive meninges stimulation. Cerebrospinal fluid pressure was extremely high; protein and glucose exceeded the standard. Cerebrospinal fluid pathogen examination excludes viruses, bacteria, fungi, tuberculosis. Cerebrospinal fluid antibody test: autoimmune encephalitis antibody, paraneoplastic syndrome antibody, AQP4 antibody, MOG antibody were negative. MRI plain scan showed no obvious abnormality. The patient was clinically diagnosed with NMOSD and was treated with methylprednisolone shock combined with IVIG. The patient's condition was still with progressive aggravation, with vision reduced to blindness, numbness and weakness of both lower limbs, and bladder and rectum dysfunction. In order to improve the patient's symptoms, second-line drugs (hydroxychloroquine, mortethaphenolate) were changed, but the patient's condition could not be reversed. Enhanced MRI showed thickening and striated enhancement of the meninges and spinal cord, suggesting meningeal carcinoma. Fresh cerebrospinal fluid was repeatedly sent for cytological examination, and the results showed that heteromorphic cells (abnormal shape, active nuclear division, naked nuclear cells, nucleolar pleomorphism) were finally diagnosed as meningeal carcinoma, classified as diffuse leptomeningeal glioneuronal tumor. However, this is inconsistent with the negative cerebrospinal fluid cytology of DLGNT. Considering the reason that the Ommaya capsule was surgically placed, the meninges were partially damaged, the tumor cells were detached, and a small amount of flocs were formed, which increased the positive rate of tumor cells detected in the cerebrospinal fluid. But this was only a single case, not enough to prove that meningeal damage could lead to cerebrospinal fluid cytology positivity.
The causes of misdiagnosis in this case include (1) adolescent female, no history of primary tumor, acute onset, obvious visual impairment, similar to the onset of NMOSD; (2) CSF of NMOSD and DLGNT have no specificity, NMOSD may be negative for AQP4 antibody, and the DLGNT cytology examination was negative; (3) MRI scan of some NMOSD and DLGNT was difficult in finding abnormal signals of the optic nerve, brain, and spinal cord, and there was false negative in enhanced MRI; (4) DLGNT is rare, and the relevant experience of the first-time physicians is little.
The visual impairment and spinal cord injury of the patient were similar to those of NMOSD, but the patient had severe headache; high protein and intracranial pressure; negative AQP4, MOG, and other antibodies; no history of infection before the onset; no rapid paraplegia; no spinal cord segmental abnormal signals; and ineffective immune treatment, which was inconsistent with NMOSD. Compared with multiple sclerosis, the age of onset was similar, with vision loss, spinal cord involvement, motor sensory disturbance, high cerebrospinal fluid pressure, high protein, and spinal membrane enhancement. However, there was no family history and no history of pre-onset infection. MRI showed no sclerosing plaques and no specific oligoclonal band antibodies, and immune therapy was ineffective compared with VKH syndrome, although there were headaches, visual impairment, high protein, and high intracranial pressure. Most of the patients with VKH syndrome are male, with a history of infection before the onset, fever, effective immunotherapy, and rare spinal cord involvement.
The innovations of this paper are (1) there are differences between this patient and the literature reports on DLGNT: adolescents, no history of tumor, no extracranial tumor lesions, rapid vision loss, protein is super high, and more different is excessive glucose; (2) detailed description of the process of misdiagnosis as NMOSD, enhanced MRI, and CSF cytological features; (3) classic meningeal carcinoma, NMOSD, multiple sclerosis, VKH syndrome, and etc. have similar clinical manifestations and diagnosis and treatment methods, which reflect the uniqueness of this paper; (4) proposes that when diseases such as viral encephalitis, tuberculous encephalitis, cryptococcal encephalitis, and suppurative encephalitis were excluded, immune treatment was ineffective, and DLGNT should be taken into account regardless of the previous tumor history and age of onset, and the diagnosis should be made as soon as possible through CSF cytology and enhanced MRI.
Limitations
(1) Without biopsy, it was difficult to accurately classify from histology; (2) for exfoliated cells in cerebrospinal fluid, no marker examination (OLIG-2, p53, GFAP); (3) after diagnosis, the patient gave up treatment. Although there were telephone follow-ups, it was difficult to track the changes of disease condition; (4) this article lacks large samples. Further collection of relevant cases is required to provide clinical data for the diagnosis and treatment of the disease.
Conclusions
The clinical manifestations of DLGNT are diverse and nonspecific and difficult to diagnose, and there is no targeted treatment. Early diagnosis and treatment are the keys to improve the prognosis. The disease is easily confused with viral encephalitis, tuberculous encephalitis, neoformococcal encephalitis, NMOSD, multiple sclerosis, and VKH syndrome. When patients have unexplained high cranial pressure, difficult to characterize meningeal lesions, cranial nerve paralysis, intractable headache, or malignant tumor with abnormal mental behavior, we should be vigilant against DLGNT. Cerebrospinal fluid tumor cytology and head-enhanced MRI scanning examination were performed in time to enable patients to be diagnosed and treated in time to improve the quality of life and prolong life. However, the positive rate of cerebrospinal fluid cytology is low, and it is necessary to send fresh specimens several times. Cytologists need to improve the recognition ability of tumor cells to improve the detection rate. CNS tumors release tDNA into the cerebrospinal fluid, which opens the door to accurate clinical trials using cerebrospinal fluid tDNA as a biomarker. In addition, the rapid development of molecular targeted therapy has brought hope to the individualized treatment of DLGNT.
